Solventum Corporation (SOLV)
$
85.43
+0.17 (0.20%)
Key metrics
Financial statements
Free cash flow per share
0.2869
Market cap
13.1 Billion
Price to sales ratio
1.5619
Debt to equity
1.0303
Current ratio
1.5000
Income quality
0.3235
Average inventory
1 Billion
ROE
0.4104
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Solventum Corporation, a healthcare company incorporated in 2023 and based in Saint Paul, Minnesota, is focused on developing, manufacturing, and commercializing a diverse range of solutions to meet critical customer and patient needs. The company operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment offers an array of products, including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. Meanwhile, the Dental Solutions segment provides an extensive suite of dental and orthodontic products such as brackets, aligners, restorative cements, and bonding agents. Health Information Systems is dedicated to delivering software solutions like computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. In addition, the Purification and Filtration segment features advanced purification and filtration technologies encompassing filters, purifiers, cartridges, and membranes. The company's operating expenses amount to $3,557,000,000.00 encompassing various operational costs incurred. With reported revenue of $8,254,000,000.00 the company reflects a strong market presence. Moreover, the operating income ratio stands at 0.13 indicating the company's operational profitability margin, while the weighted average number of shares outstanding is 173,200,000.00 highlighting the company's shareholder base. The company's stock is identified with the symbol 'SOLV' in the market. Investors will find the stock reasonably priced at $73.72 appealing to a broad range of market participants. With an average trading volume of 1,099,469.00 the stock indicates moderate liquidity, which can facilitate trading activities for shareholders. Solventum Corporation boasts a mid-range market capitalization of $14,817,371,922.00 establishing it as a steady performer. As a key player in the Medical - Care Facilities industry, the company significantly contributes to the overall market landscape, driving innovation and growth within the healthcare sector, wherein it belongs to the Healthcare sector. This combination of solid financial performance and strategic positioning underscores Solventum Corporation’s potential as a valuable investment opportunity within the dynamic healthcare market.
Is Solventum Corporation (SOLV) a good investment?
Investing in Solventum Corporation (SOLV) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A, with a Bullish outlook. Always conduct your own research before investing.
What is Solventum Corporation (SOLV)'s stock forecast?
Analysts predict Solventum Corporation stock to fluctuate between $60.70 (low) and $88.20 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Solventum Corporation's market capitalization?
As of 2025-12-05, Solventum Corporation's market cap is $14,817,371,922, based on 173,444,597 outstanding shares.
How does Solventum Corporation compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Solventum Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy Solventum Corporation (SOLV) stock?
To buy Solventum Corporation (SOLV) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SOLV. Place an order (Market, Limit, etc.).
What is the best time to invest in Solventum Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Solventum Corporation perform in the last earnings report?
Revenue: $8,254,000,000 | EPS: $2.77 | Growth: -64.44%.
Where can I find Solventum Corporation's investor relations reports?
Visit https://www.solventum.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Solventum Corporation?
You can explore historical data from here
What is the all-time high and low for Solventum Corporation stock?
All-time high: $88.20 (2025-12-02) | All-time low: $47.16 (2024-07-16).
What are the key trends affecting Solventum Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Solventum Corporation (SOLV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
seekingalpha.com
Solventum Corporation ( SOLV ) Stifel 2025 Healthcare Conference November 12, 2025 11:20 AM EST Company Participants Wayde McMillan - Chief Financial Officer Doug Bartlett Conference Call Participants Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Frederick Wise Stifel, Nicolaus & Company, Incorporated, Research Division Luckily, Wayde is not the Chief Executive Officer. He tells me, I'm not sure.
zacks.com
Investors interested in Medical Services stocks are likely familiar with Solventum (SOLV) and Danaher (DHR). But which of these two stocks offers value investors a better bang for their buck right now?
seekingalpha.com
Solventum which has barely moved since our coverage 14 months back, delivered mixed Q3 results last week. SOLV managed to beat both topline and bottomline estimates (although the degree of beat on the latter wasn't as strong as previous quarters), but revenue trends continue to slow. Margin pressures persist due to tariffs (the impact of which will be worse next year), but SOLV's new multi-year restructuring program and its ongoing efforts on programmatic savings may provetobehandy.
zacks.com
Investors with an interest in Medical Services stocks have likely encountered both Solventum (SOLV) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
zacks.com
Solventum posts strong Q3 results with a revenue and earnings beat, lifts 2025 EPS guidance on solid MedSurg and HIS growth.
seekingalpha.com
Solventum Corporation ( SOLV ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Amy Wakeham - Senior Vice President of Investor Relations & External Finance Communications Bryan Hanson - CEO & Director Wayde McMillan - Chief Financial Officer Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Steven Valiquette - Mizuho Securities USA LLC, Research Division Jason Bednar - Piper Sandler & Co., Research Division Travis Steed - BofA Securities, Research Division Lei Huang - Wells Fargo Securities, LLC, Research Division Presentation Operator Good afternoon. My name is Regina, and I will be your conference operator today.
zacks.com
Solventum (SOLV) came out with quarterly earnings of $1.5 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.64 per share a year ago.
zacks.com
Solventum's Q3 results may reflect softer sales and tariff impacts, though pricing discipline and core growth drivers likely aided margins.
seekingalpha.com
Solventum Corporation looks increasingly attractive after divesting its Purification & Filtration business, reducing debt, and improving organic growth. SOLV raised the full-year earnings guidance twice, now projecting $5.88-$6.03 per share, reflecting solid momentum and successful execution. Despite a reasonable 12x earnings multiple and lower leverage, heavy earnings adjustments and spin-off costs temper near-term cash flow conversion.
See all news
